TL;DR
In a placebo-controlled phase I trial of 40 people with MASLD, a single injection of CIDEB siRNA was followed by liver-fat reductions of up to 80.3% at 36 weeks. The early results also showed lower ALT levels, but the trial was small and was not designed to establish clinical benefit; the treatment is now being studied in phase II and phase III trials.
An experimental small interfering RNA treatment called CIDEBsiRNA was associated with large reductions in liver fat after one injection in a 40-person phase I trial involving people with metabolic dysfunction-associated steatotic liver disease (MASLD), according to results reported November 10. At 36 weeks, the highest-dose group had an average 80.3% reduction from baseline; researchers say the findings are preliminary, and the study was not designed to prove clinical benefit.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The placebo-controlled trial assigned participants to one subcutaneous dose of CIDEBsiRNA at 15, 60, 200 or 600 milligrams, or to placebo. At week 36, average liver-fat changes from baseline ranged from 57.8% lower in the 15-mg group to 80.3% lower in the 600-mg group. The placebo group had a 2.9% decrease. These figures describe average relative changes, not percentage-point changes in liver-fat content.
Across the treatment groups, 62% of participants had liver fat below 5% at week 36, the threshold used in the report for normalized liver fat; none of the placebo participants reached that level. A relative liver-fat reduction of at least 30% was recorded in 93% of treated participants and 10% of those given placebo. The report says that degree of reduction has been linked with histological improvement, but it does not establish that participants had fewer symptoms or complications.
Mean ALT, a liver enzyme measured in blood, fell 32% by week 12 among treated participants, while the placebo group’s mean rose 5%. At week 36, ALT in the 600-mg group was down 36.5% from baseline, compared with a 6.6% increase in the placebo group. Treatment-emergent adverse events occurred in 87% of treated participants and 90% of placebo participants; events judged related to the study drug were reported in 10% of treated participants and none in the placebo group.
Potential for Less Frequent Treatment
The results offer an early signal that targeting a liver-fat pathway may produce lasting changes after a single injection. If later trials confirm the effect and establish an acceptable safety profile, a treatment that can be given infrequently could add an option for people with MASLD, a condition affecting a large number of adults. The trial’s follow-up lasted 36 weeks, however, and does not show whether these changes reduce the likelihood of liver scarring, liver failure, cancer or other clinical outcomes.
The distinction matters because liver-fat reduction is a measurement, not proof of disease reversal. ALT changes are also laboratory findings. The study supports further testing, but it cannot establish that CIDEBsiRNA prevents progression or improves how patients feel or function.
Products Worth Considering

Levoit Core 400S-P Smart Air Purifier for Large Rooms

Levoit Vital 200S-P Smart Air Purifier for Large Rooms (up to 1875 ft²)

Therabody Theragun Relief Massage Gun, 3-Speed, Navy
As an affiliate, we earn on qualifying purchases.
How CIDEBsiRNA Targets Liver Fat
CIDEBsiRNA, also called ALN-CIDEB, targets the messenger RNA coded by the CIDEB gene in liver cells. The gene is involved in controlling the size of liver fat droplets. The report notes that people with loss-of-function CIDEB gene mutations have lower risks of MASLD, MASH and cirrhosis; the treatment is designed to act on the same biological target, but its trial results remain preliminary.
Participants had MASLD, a body mass index of 30 to 40, and liver fat of at least 8.5%. Their average age was 40.4 years, average BMI was 34.2, and average liver fat measured by MRI was 14.3%. Most were male, and one quarter had type 2 diabetes. The report says many participants did not have elevated liver enzymes or fibrosis at baseline, limiting how well the findings may apply to people with more advanced disease.
The source report estimates that as many as 85 million U.S. adults have MASLD and says no drugs are specifically indicated for the disease. Current management includes lifestyle measures such as diet, exercise and weight loss. An estimated 25% to 30% of people with MASLD may develop MASH, which can progress to fibrosis and impaired liver function.
“We know that if we manage to reduce the amount of fat in the liver, this correlates very favorably with clinical outcomes.”
— Jörg Täubel, MD, of Richmond Pharmacology, presenting at the AASLD annual Liver Meeting
Questions on Benefit and Safety
The phase I trial included only 40 participants and was not powered for statistical inference, according to the report. Its findings cannot settle how reliably the treatment works across a broader population or whether liver-fat and ALT changes lead to fewer cases of fibrosis or other complications. The available source does not provide detailed outcomes beyond the 36-week follow-up.
Baseline characteristics also limit interpretation: most participants did not have elevated liver enzymes or fibrosis, and the report cautions that results may not generalize to people with more advanced MASLD, including MASH. Although overall adverse-event rates were similar between groups, the small study cannot establish the risks of less common or longer-term effects. The report does not provide a full breakdown of the severity of drug-related events.
Larger Trials Will Test the Signal
CIDEBsiRNA has advanced to a phase II trial for MASH and a phase III trial for MASLD, according to the report. Those studies will need to assess whether the liver-fat changes can be reproduced in larger groups, how long they last, and how the treatment performs across different levels of disease severity.
Further trial results will also be needed to clarify longer-term safety and whether improvements in imaging and blood tests translate into meaningful health benefits. Until those data are available, CIDEBsiRNA remains an investigational treatment rather than an established MASLD therapy.
Key Questions
How much did liver fat fall in the trial?
At 36 weeks, average liver-fat reductions from baseline ranged from 57.8% to 80.3% across the four CIDEBsiRNA dose groups. The highest-dose group had the largest average reduction; placebo participants had a 2.9% decrease.
Did the treatment normalize liver fat for participants?
By week 36, 62% of treated participants had liver-fat content below 5%, the report’s threshold for normalization. No placebo participants reached that threshold during the study.
Does the trial show that CIDEBsiRNA treats or reverses MASLD?
No. This was a small phase I study that measured liver fat and blood tests. It was not designed to establish that the treatment prevents disease progression, reverses liver damage or improves long-term health outcomes.
What side effects were reported?
Treatment-emergent adverse events occurred in 87% of CIDEBsiRNA recipients and 90% of placebo recipients. Events considered related to the study drug were reported in 10% of treated participants and none receiving placebo. Larger and longer studies are needed to characterize safety.
What happens next for the treatment?
According to the report, CIDEBsiRNA has entered a phase II trial for MASH and a phase III trial for MASLD. Those studies are expected to provide evidence from larger groups and further assess efficacy and safety.
Source: medpagetoday.com
